Journal of the Egyptian National Cancer Institute最新文献

筛选
英文 中文
Current and future of targeted therapies against BCR::ABL kinases. 靶向治疗BCR: ABL激酶的现状和未来。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-04-07 DOI: 10.1186/s43046-025-00263-5
Sridhar Jayavel, Manasvini Subramanian, Pradeep Kumar Kesavan, Suresh Jayavel
{"title":"Current and future of targeted therapies against BCR::ABL kinases.","authors":"Sridhar Jayavel, Manasvini Subramanian, Pradeep Kumar Kesavan, Suresh Jayavel","doi":"10.1186/s43046-025-00263-5","DOIUrl":"10.1186/s43046-025-00263-5","url":null,"abstract":"<p><p>Chronic myeloid leukemia (CML) is a kind of leukemia that arises due to the translocation betwixt chromosomes 9 and 22. Philadelphia chromosome is characterized by the BCR::ABL fusion gene, which results from this recombination. It transcribes into active tyrosine kinase variants such as P185, P190, P210, and P230, depending on breakpoint chain variations. The fusion protein, encodes tyrosine kinases with varying exons, resulting in uncontrollable ATP-utilizing downstream signaling activities. Targeted therapy with various tyrosine kinase inhibitors (TKIs) is used to combat BCR::ABL fusion kinases and increase the survival rate of patients. However, the incidence of TKI resistance among CML patients is widely noticed around the world. Hence, an elaborate and accurate understanding of the structural interactions between BCR::ABL encoded tyrosine kinases, which are responsible for sensitivity and resistance, is mandatory for hassle-free targeted therapy. This review is intended to cover the reported structural interactions between BCR::ABL variants and TKI ligands in detail to highlight strategies that may be applied in the near future to overcome the resistance and other cross-reactions.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"12"},"PeriodicalIF":2.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin cancers diagnosed at the dermatology department of a tertiary hospital in Jordan over one year. 在约旦一家三级医院的皮肤科诊断出一年多的皮肤癌。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-03-31 DOI: 10.1186/s43046-025-00268-0
Jehad Shaher Alassaf, Laith Alabed, Salah Abdallat, Hamzeh Khair, Omar Ashokaibi, Hayat Khassawneh
{"title":"Skin cancers diagnosed at the dermatology department of a tertiary hospital in Jordan over one year.","authors":"Jehad Shaher Alassaf, Laith Alabed, Salah Abdallat, Hamzeh Khair, Omar Ashokaibi, Hayat Khassawneh","doi":"10.1186/s43046-025-00268-0","DOIUrl":"10.1186/s43046-025-00268-0","url":null,"abstract":"<p><strong>Introduction: </strong>Skin tumours comprise an important fraction of dermatology practice. Skin tumours can be benign or malignant, and patients can present with a merely unsightly nodule to a rapidly growing nodule. The diagnosis is made on pathological basis, which is done after performing skin biopsies.</p><p><strong>Aim: </strong>In this study, we aim to describe the characteristics of malignant skin tumors diagnosed by skin biopsies over a one-year period (2023) at the Department of Dermatology, King Hussein Medical Center (KHMC).</p><p><strong>Methods: </strong>In this retrospective study, data from biopsies that were done at our department and diagnosed as skin cancers were collected, patients' demographics were registered; including age, gender, and tumour location, and final diagnosis was recorded. Data was registered on an Excel® datasheet and analyzed using simple statistical methods.</p><p><strong>Results: </strong>There were 78 biopsies that were diagnosed as skin cancers at the department of Dermatology. Of these, the most common diagnosis was basal cell carcinoma with 38% of the biopsied cancers. Eighteen per cent were diagnosed as squamous cell carcinomas, and 15% were melanomas. Mycosis fungoides and cutaneous T cell lymphoma cases were included in this study and reached 18% of the diagnosed skin cancers in our patients.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"10"},"PeriodicalIF":2.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of noncoding RNA as a pacemaker in cancer stem cell regulation: a review article. 非编码RNA作为起搏器在肿瘤干细胞调控中的作用综述
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-03-24 DOI: 10.1186/s43046-025-00266-2
Yasmin M Attia, Samer A Tadros, Sally A Fahim, Doaa M Badr
{"title":"Role of noncoding RNA as a pacemaker in cancer stem cell regulation: a review article.","authors":"Yasmin M Attia, Samer A Tadros, Sally A Fahim, Doaa M Badr","doi":"10.1186/s43046-025-00266-2","DOIUrl":"10.1186/s43046-025-00266-2","url":null,"abstract":"<p><p>Accumulated evidence supported the crucial role of a tiny population of cells within the tumor called cancer stem cells (CSCs) in cancer origination, and proliferation. Additionally, these cells are distinguished by their self-renewal, differentiation, and therapeutic resistance capabilities. Interestingly, many studies recorded dysregulation of different types of noncoding RNAs, such as microRNA (miRNA) and long non-coding RNA (LncRNA), in cancer cells as well as CSCs. Moreover, several studies also supported the regulation of the transcription factors and signaling pathways required for CSC progression by these noncoding RNAs. However, the exact biological functions of all these noncoding RNAs are not well understood yet. These findings are of great interest, implying usage of noncoding RNA as therapeutic tool to target these cells. In this review, we provide an insight into how noncoding RNAs regulate CSCs and how this correlation is manipulated to develop new therapies to eradicate cancer cells successfully.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"9"},"PeriodicalIF":2.1,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of prostate biopsy outcomes at different cut-offs of prostate-specific antigen using machine learning: a multicenter study. 使用机器学习预测前列腺特异性抗原不同截断点的前列腺活检结果:一项多中心研究。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-03-17 DOI: 10.1186/s43046-025-00265-3
Mostafa A Arafa, Karim H Farhat, Sherin F Aly, Farrukh K Khan, Alaa Mokhtar, Abdulaziz M Althunayan, Waleed Al-Taweel, Sultan S Al-Khateeb, Sami Azhari, Danny M Rabah
{"title":"Prediction of prostate biopsy outcomes at different cut-offs of prostate-specific antigen using machine learning: a multicenter study.","authors":"Mostafa A Arafa, Karim H Farhat, Sherin F Aly, Farrukh K Khan, Alaa Mokhtar, Abdulaziz M Althunayan, Waleed Al-Taweel, Sultan S Al-Khateeb, Sami Azhari, Danny M Rabah","doi":"10.1186/s43046-025-00265-3","DOIUrl":"10.1186/s43046-025-00265-3","url":null,"abstract":"<p><strong>Background: </strong>Machine learning (ML) is a significant area of artificial intelligence, which can improve the accuracy of predictive or diagnostic models for differentiating between prostate biopsy outcomes. This study aims to develop a novel decision-support ML model for classifying patients with biopsy-negative (cancer-free), clinically significant, and non-clinically significant prostate cancer across two prostate-specific antigen (PSA) cut-offs ≤ 10 ng/ml and > 10 ng/ml.</p><p><strong>Methods: </strong>The data for the current study were retrieved from the records of two main hospitals in Riyadh, Saudi Arabia from July 2018 through July 2024. Six machine learning algorithms were employed, and the dataset was randomly divided into a training set and a validation set at a ratio of 8:2. The following metrics were used as performance indicators across the six algorithms: Accuracy, Precision, Recall, F1-score, and area under the curve. Recent data from the two hospitals was utilized for external validation.</p><p><strong>Results: </strong>The metrics for Random Forest, Extra Tree, and Decision Tree algorithms showed excellent capability in classifying the outcomes of prostate biopsy for the two PSA cut-offs. However, the metrics for the PSA cut-off > 10 ng/ml are higher than those for PSA ≤ 10 ng/ml. For the three-class classification, the accuracy and area under the curve for the cut-off > 10 ng/ml were 0.96 and 0.99, respectively. While for the cut-off ≤ 10 ng/ml they were 0.92 and 0.94 for Random Forest and 0.94 and 0.95 for the Extra Tree algorithm. The metrics of non-clinically significant and biopsy-negative cases outperformed those of clinically significant cases.</p><p><strong>Conclusion: </strong>ML models are proving to be effective tools in differentiating between prostate biopsy outcomes, enhancing diagnostic accuracy, and potentially transforming clinical practices in prostate cancer management.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"8"},"PeriodicalIF":2.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation. 探讨5-氟尿嘧啶、百里醌和辅酶Q10三联疗法对结肠癌细胞糖酵解和氧化还原状态调节的潜在加性作用。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-03-10 DOI: 10.1186/s43046-025-00261-7
Akhmed Aslam, Faisal Minshawi, Hussain Almasmoum, Riyad Almaimani, Aiman Alsaegh, Amani A Mahbub, Mohammad S Iqbal, Aisha Tabassum, Mohamed E Elzubier, Shakir Idris, Wesam F Farrash, Bassem Refaat
{"title":"Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation.","authors":"Akhmed Aslam, Faisal Minshawi, Hussain Almasmoum, Riyad Almaimani, Aiman Alsaegh, Amani A Mahbub, Mohammad S Iqbal, Aisha Tabassum, Mohamed E Elzubier, Shakir Idris, Wesam F Farrash, Bassem Refaat","doi":"10.1186/s43046-025-00261-7","DOIUrl":"10.1186/s43046-025-00261-7","url":null,"abstract":"<p><strong>Background: </strong>To investigate the anticancer effects of 5-Fluorouracil (5-FU), thymoquinone (TQ), and/or coenzyme Q10 (CQ10), alone and combined, in HT29, SW480, and SW620 human colorectal cancer (CRC) cell lines.</p><p><strong>Methods: </strong>Cell cycle progression and apoptosis were assessed by flow cytometry. Gene and protein expression of molecules involved in apoptosis (BLC2, survivin, BAX, Cytochrome-C, and Caspase-3), cell cycle (CCND1, CCND3, p21, and p27), the PI3K/AKT/mTOR/HIF1α oncogenic pathway, and glycolysis (LDHA, PDH, and PDHK1) were also analysed by quantitative RT-PCR and Western blot. Oxidative stress markers (ROS/RNS, MDA, and Protein carbonyl groups) and antioxidants (GSH and CAT) were quantified by ELISA.</p><p><strong>Results: </strong>All treatments resulted in anticancer effects depicted by cell cycle arrest and apoptosis, with TQ demonstrating greater efficacy than CQ10, both with and without 5-FU. However, 5-FU/TQ/CQ10 triple therapy exhibited the most potent pro-apoptotic activity in all cell lines, portrayed by the lowest levels of oncogenes (CCND1, CCND3, BCL2, and survivin) and the highest upregulation of tumour suppressors (p21, p27, BAX, Cytochrome-C, and Caspase-3). The triple therapy also showed the strongest suppression of the PI3K/AKT/mTOR/HIF1α pathway, with a concurrent increase in its endogenous inhibitors (PTEN and AMPKα) in all cell lines used. Additionally, the triple therapy favoured glucose oxidation by upregulating PDH, while decreasing LDHA and PDHK1 enzymes. The triple therapy also displayed the most significant decline in antioxidant levels and the highest increases in oxidative stress markers.</p><p><strong>Conclusions: </strong>This study is the first to demonstrate the superior anticancer effects of TQ compared to CQ10, with and without 5-FU, in CRC treatment. Moreover, this is the first report to reveal improved anticancer effects of the 5-FU/TQ/CQ10 triple therapy, potentially through promoting oxidative phosphorylation, attenuating the PI3K/AKT/mTOR/HIF1α pathway, and increasing oxidative stress-induced apoptosis.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"7"},"PeriodicalIF":2.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer. 释放抗体-药物偶联物靶向非小细胞肺癌分子生物标志物的治疗潜力。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-03-03 DOI: 10.1186/s43046-025-00264-4
Shruti Soni, Kaivalya Megha, Vraj B Shah, Aayushi C Shah, Shelly Bhatt, Manthan Merja, Avinash Khadela
{"title":"Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer.","authors":"Shruti Soni, Kaivalya Megha, Vraj B Shah, Aayushi C Shah, Shelly Bhatt, Manthan Merja, Avinash Khadela","doi":"10.1186/s43046-025-00264-4","DOIUrl":"10.1186/s43046-025-00264-4","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is a prevalent and lethal malignancy worldwide, posing significant challenges to patient survival. Recent advancements in the field of oncology have introduced immunotherapy and targeted therapy as primary treatment modalities for NSCLC. However, the emergence of treatment resistance and relapse has impeded their long-term effectiveness. Antibody-drug conjugates (ADCs), a rapidly evolving class of anti-cancer agents, offer a promising solution to this issue by harnessing the specificity of monoclonal antibodies and the cytotoxic potency of drug payloads. ADCs have demonstrated notable potential in targeting both highly expressing and low-expressing malignant cells, with early-phase clinical trials yielding superior survival outcomes in NSCLC patients. This review comprehensively outlines the recent advancements in ADC-based strategies for managing NSCLC, supported by evidence from clinical trials. Additionally, the review delves into the oncogenic mechanisms of various biomarkers and offers insights into strategies for their detection in NSCLC patients. Lastly, a forward-looking perspective is provided to address the challenges associated with the utilization of ADCs in NSCLC therapy.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"6"},"PeriodicalIF":2.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of key biomarkers in breast cancer based on bioinformatics analysis and experimental verification. 基于生物信息学分析和实验验证的乳腺癌关键生物标志物鉴定。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-02-24 DOI: 10.1186/s43046-025-00260-8
Yu Huan, Ping She, Xushan Cai, Jiehua Qi, Chunli Zhang
{"title":"Identification of key biomarkers in breast cancer based on bioinformatics analysis and experimental verification.","authors":"Yu Huan, Ping She, Xushan Cai, Jiehua Qi, Chunli Zhang","doi":"10.1186/s43046-025-00260-8","DOIUrl":"10.1186/s43046-025-00260-8","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is a malignant tumor characterized by a high incidence rate and is the leading cause of cancer-related deaths among women worldwide. This study aims to identify key genes and potential prognostic biomarkers using a bioinformatics approach.</p><p><strong>Methods: </strong>Three microarray datasets, GSE86374, GSE120129, and GSE29044, were downloaded from the GEO database. GEO2R and Venn diagram software were employed to identify differentially expressed genes (DEGs), while DAVID was utilized for functional enrichment analysis. Subsequently, STRING and Cytoscape were used to construct the protein-protein interaction (PPI) network among the DEGs. UALCAN, GEPIA, and the Kaplan-Meier plotter were employed for prognostic analysis. Following this, the correlations and alterations of key genes were examined using cBioPortal. Finally, immunohistochemistry (IHC) was performed to validate the expression levels of the key genes.</p><p><strong>Results: </strong>A total of 323 differentially expressed genes (DEGs) were identified. From the protein-protein interaction (PPI) network, 37 hub genes were selected. Validation using UALCAN, GEPIA, and Kaplan-Meier plotters revealed that three key genes-RACGAP1, SPAG5, and KIF20A-were significantly overexpressed and associated with poor prognosis in breast cancer (BC), as well as advanced tumor staging. The correlations and alterations of these key genes, as demonstrated on cBioPortal, indicated that their alterations co-occurred. Experimental verification through immunohistochemistry (IHC) confirmed that the proteins of these key genes were highly expressed in tumor tissues.</p><p><strong>Conclusions: </strong>The key genes identified in this study can enhance our understanding of the molecular mechanisms underlying breast cancer (BC). Additionally, these genes may serve as potential sensitive biomarkers for patients with BC.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"5"},"PeriodicalIF":2.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective observational study of oral clonazepam to prevent high-dose busulfan-induced seizures in adult patients. 口服氯硝西泮预防成人患者大剂量布苏芬诱发癫痫发作的前瞻性观察研究。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-02-03 DOI: 10.1186/s43046-025-00257-3
María Sacramento Díaz-Carrasco, Andrés Sánchez-Salinas, Juan José Fernández-Ávila, Raquel Olmos-Jiménez, Ignacio Español-Morales, Alberto Espuny-Miró
{"title":"Prospective observational study of oral clonazepam to prevent high-dose busulfan-induced seizures in adult patients.","authors":"María Sacramento Díaz-Carrasco, Andrés Sánchez-Salinas, Juan José Fernández-Ávila, Raquel Olmos-Jiménez, Ignacio Español-Morales, Alberto Espuny-Miró","doi":"10.1186/s43046-025-00257-3","DOIUrl":"10.1186/s43046-025-00257-3","url":null,"abstract":"<p><strong>Background: </strong>Busulfan at high doses has been associated with a risk of seizures. Phenytoin has been used traditionally as anti-seizure prophylaxis, and benzodiazepines and levetiracetam have been introduced more recently, providing data from retrospective series. The main purpose of this study was to evaluate the effectiveness of oral clonazepam as anti-seizure prophylaxis in adult patients receiving high doses of intravenous busulfan as part of the conditioning regimen for hematopoietic stem cell transplantation. The secondary objectives were to determine the feasibility of this regimen and to analyze the adverse events associated with the use of clonazepam.</p><p><strong>Methods: </strong>This prospective, single-center study included 64 adult patients who received conditioning regimens with high doses of intravenous busulfan and anti-seizure prophylaxis with oral clonazepam, at a dose of 1 mg/8 h, from 12 h before starting treatment with busulfan until 48 h after ending administration.</p><p><strong>Results: </strong>The effectiveness of the prophylaxis was 100%, with no episodes of seizures during busulfan treatment or in the 72 h afterwards. Treatment was feasible, and oral scheduled administration was completed in all patients. Adverse events that could be associated with clonazepam included the onset of somnolence, dizziness, and confusion, mostly mild.</p><p><strong>Conclusion: </strong>The oral clonazepam regimen described in this study has been prospectively shown to be an effective, feasible anti-seizure prophylaxis option with manageable toxicity.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"4"},"PeriodicalIF":2.1,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative study between central quadrantectomy and nipple resection with areola preservation Versus Grisotti flap mammoplasty in central breast lesions extending to nipple: a randomized clinical trial. 中心四象限切除术和乳晕保留乳头切除术与Grisotti皮瓣乳房成形术治疗延伸至乳头的乳房中央病变的比较研究:一项随机临床试验。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-01-20 DOI: 10.1186/s43046-024-00253-z
Philobater Bahgat Adly Awad, Basma Hussein Abdelaziz Hassan, Abanoub Adel Shafek Awad, Abdelrahman Ahmed Younis Mohamed Attaia, Kerolos Bahgat Adly Awad, Dina Mohamed Hanafy, Ahmed Gamal El Din Osman
{"title":"A comparative study between central quadrantectomy and nipple resection with areola preservation Versus Grisotti flap mammoplasty in central breast lesions extending to nipple: a randomized clinical trial.","authors":"Philobater Bahgat Adly Awad, Basma Hussein Abdelaziz Hassan, Abanoub Adel Shafek Awad, Abdelrahman Ahmed Younis Mohamed Attaia, Kerolos Bahgat Adly Awad, Dina Mohamed Hanafy, Ahmed Gamal El Din Osman","doi":"10.1186/s43046-024-00253-z","DOIUrl":"10.1186/s43046-024-00253-z","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate central quadrantectomy and nipple resection with areola preservation (CQ-NR-AP) as a new reconstructive oncoplastic technique Versus Grisotti flap mammoplasty (GFM) in central malignant tumors of the breast extending to the nipple, in terms of time procedures, breast symmetry, patient satisfaction, postoperative complications, and local recurrence.</p><p><strong>Patients and methods: </strong>The current study is a single-blind, single-center, randomized, controlled trial that was performed between May 2018 and May 2023 in the breast surgery unit of University Hospitals. This trial involved 40 individuals who had central breast lesions that extended to the nipple and were monitored for two years following surgery.</p><p><strong>Results: </strong>As regards the mean intra-operative time in minutes, in the group (I) was 80.1 with a standard deviation of ± 13.9, and ingroup (II) was 138.9 with a standard deviation of ± 14.02 (p = 0.001). The seroma was detected in zero cases in group (I) and 2(10%) cases in group II (p = 0.487) and those two cases were managed by aspiration only. Regarding, the wound infection was found in one case (5%) in group (I) and 3(15%) cases in group II (p = 0.605). Regarding patient satisfaction and breast, symmetry was much better in the group (I).</p><p><strong>Conclusion: </strong>The safety and ease of central quadrantectomy and nipple resection with areola preservation were demonstrated in a two-year follow-up, with a lower incidence of complications compared to the Grisotti flap mammoplasty technique. Furthermore, this approach was associated with higher patient satisfaction, which is a significant achievement in the management of centrally located breast tumors.</p><p><strong>Trial registration: </strong>PACTR202405688323721. 28/05/2024.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"3"},"PeriodicalIF":2.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Susceptibility of different mice species to chemical induction of colorectal cancer by 1,2-dimethylhydrazine. 不同鼠种对1,2-二甲基肼化学诱导结直肠癌的易感性。
IF 2.1
Journal of the Egyptian National Cancer Institute Pub Date : 2025-01-13 DOI: 10.1186/s43046-024-00255-x
Nourhan M Abdelmaksoud, Ahmed I Abulsoud, Tamer M Abdelghany, Shereen Saeid Elshaer, Ahmed Samaha, Nadine W Maurice, Sherine Maher Rizk, Mahmoud A Senousy
{"title":"Susceptibility of different mice species to chemical induction of colorectal cancer by 1,2-dimethylhydrazine.","authors":"Nourhan M Abdelmaksoud, Ahmed I Abulsoud, Tamer M Abdelghany, Shereen Saeid Elshaer, Ahmed Samaha, Nadine W Maurice, Sherine Maher Rizk, Mahmoud A Senousy","doi":"10.1186/s43046-024-00255-x","DOIUrl":"10.1186/s43046-024-00255-x","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a major public health concern. Animal models play a crucial role in understanding the disease pathology and development of effective treatment strategies. Chemically induced CRC represents a cornerstone in animal model development; however, due to the presence of different animal species with different genetic backgrounds, it becomes mandatory to study the susceptibility of different mice species to CRC induction by different chemical entities such as 1,2-dimethylhydrazine (DMH). This study aimed to investigate the induction receptivity of two commonly used mice species, C57BL/6 and BALB/c, to DMH-induced CRC.</p><p><strong>Methods: </strong>Both mice species were exposed to weekly intraperitoneal injections of DMH at a dose of 20 mg/kg body weight for 15 consecutive weeks. The response to DMH was evaluated by monitoring body weight gain, daily food intake, and gastrointestinal symptoms. At the end of exposure, histopathology of distal colon dissected from both species was analyzed.</p><p><strong>Results: </strong>Results revealed that C57BL/6 had a higher response to DMH compared to BALB/c. A significant decrease in body weight gain concomitant with severe diarrhea was observed in C57BL/6 receiving DMH compared to their controls, without any difference in food intake. Histopathology of distal colon revealed aberrant crypt foci and loss of goblet cells in DMH-exposed C57BL/6 mice. On the other hand, BALB/c mice displayed a normal and intact colon, with a normal weight gain pattern, and without any gastrointestinal symptoms.</p><p><strong>Conclusion: </strong>In conclusion, C57BL/6 has a higher susceptibility toward chemical induction to CRC; therefore, it can be used to study CRC pathogenesis, prevention, and treatment.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"2"},"PeriodicalIF":2.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信